Multi-Centre, Open-Label Study to Determine the Safety and Efficacy of PEP005 [ingenol mebutate] 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)

Trial Profile

Multi-Centre, Open-Label Study to Determine the Safety and Efficacy of PEP005 [ingenol mebutate] 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Peplin
  • Most Recent Events

    • 17 Sep 2007 Status changed from in progress to completed.
    • 09 Mar 2007 Interim results have been reported.
    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top